Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Similar to Lilly's weight loss treatments (Mounjaro and Zepbound), VK2735 is a dual glucagon-like peptide ... it's important ...

The move comes after the FDA took tirzepatide, the key ingredient in Eli Lilly’s (LLY) diabetes drug Mounjaro and weight-loss ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...